Liraglutide, a GLP-1 receptor agonist sold as Victoza, becomes the second diabetes therapy to receive the cardiovascular indication.
An FDA advisory panel voted late Tuesday to update the label for the type 2 diabetes (T2D) liraglutide to state that it can lower cardiovascular (CV) risks for high-risk patients.
Liraglutide, the glucagon-like peptide-1 (GLP-1) receptor agonist sold by Novo Nordisk as Victoza, received a 17-2 vote from FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). The vote was based on results from the LEADER trial, which found a 22% reduction in the risk of CV death in high-risk patients and reduced all CV events by 13%.
If FDA approves the indication, liraglutide will become the second T2D drug and the first GLP-1 therapy to receive an indication that it can reduce CV events for high-risk patients. Empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor sold as Jardiance, was the first to receive this indication in December 2016.
Canagliflozin, the SGLT2 inhibitor sold by Janssen as Invokana, presented results at last week’s meeting of the American Diabetes Association showing a 14% reduction in cardiovascular events. Janssen has said it plans to seek a similar indication with FDA.
The panel took 2 votes on liraglutide. The first, which was 19-0, asked if the results of LEADER showed that the drug was not associated with any excess cardiovascular risk. The 17-2 vote asked if LEADER showed that there was “substantial evidence” to show that liraglutide’s 1.8 mg dose “reduces cardiovascular risk in patients with type 2 diabetes.”
Liraglutide is available in 1.2 mg and 1.8 mg injections.
“Cardiovascular disease is the number one cause of death for people with type 2 diabetes, and today’s discussion is an important reminder that there is an unmet need to provide benefits beyond (A1C) control in this population,” Todd Hobbs, MD, vice president and chief medical officer of Novo Nordisk, said in a statement. “The positive vote from EMDAC puts us one step closer to expanding our offering to reduce the risk of cardiovascular events in people with type 2 diabetes.”
The clinical trials that led to the indications were designed only to show that the diabetes drugs were safe. Results showing they reduced CV events were unexpected, and since the results for empagliflozin were announced, a trial for an investigational therapy, ertugliflozin, has expanded to find out whether it, too, prevents heart attacks, strokes, and CV deaths.
6 Blood Biomarkers Identified to Predict CVD Risk in Patients With Rheumatoid Arthritis
March 15th 2024Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen